Erratum: How common are myeloproliferative neoplasms? A systematic review and meta-analysis [Am. J. Hematol. 89:581-587, 2014. DOI: 10.1002/ajh.23690];How common are myeloproliferative neoplasms? A systematic review and meta-analysis

American Journal of Hematology

Volumn 89, Issue 6, 2014, Pages 581-587

  Titmarsh, Glen J ^a   Duncombe, Andrew S ^b   Mcmullin, Mary Frances ^a   O'Rorke, Michael ^a   Mesa, Ruben ^c   De Vocht, Frank ^d   Horan, Sarah ^e   Fritschi, Lin ^f   Clarke, Mike ^a   Anderson, Lesley A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c Mayo Clinic Cancer Centre   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e CITY UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA AND NEW ZEALAND; DATA BASE; ELECTRONIC MEDICAL RECORD; EMBASE; EUROPE; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NORTH AMERICA; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTHEMIA;

HUMANS; INCIDENCE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84900866397     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23984     Document Type: Erratum

References (78)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
2. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007 138:819-821.
3. Harrison C, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352-375.
4. Reilly J, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012;158:453-471.
5. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol 1998;5:327-331.
6. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006;107:4214-4222.
7. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29:2410-2415.
8. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664-2670.
9. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
10. Barbui T, Tefferi A. Myeloproliferative Neoplasms: Critical Concepts and Management, 2012th ed. New York: Springer; 2012.
11. Anderson L, Duncombe AS, Hughes M, et al. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 2011;87:175-182.
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
13. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010;91:174-179.
14. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2003;200-224.
15. Tefferi A. The history of myeloproliferative disorders: Before and after Dameshek. Leukemia 2008;22:3-13.
16. Seer.cancer.gov. SEER Cancer Statistics. seer.cancer.gov. 2013.
17. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
18. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leuk Off J Leuk Soc Am Leuk Res Fund 2010;24:1128-1138.
19. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;131210053122003.
20. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;131210053122003.
21. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988-992.
22. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leuk Off J Leuk Soc Am Leuk Res Fund 2008;22:1841-1848.
23. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005;105:4604-4612.
24. Fröhling S, Scholl C, Gilliland DG, et al. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-6295.
25. Prochazka AV, Markowe HLJ. The epidemiology of polycythaemia rubra vera in England and Wales 1968-1982. Br J Cancer 1986;53:59-64.
26. McNally RJ, Rowland D, Roman E, et al. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. Leuk Res Fund Centre Clin Epidemiol 1997;15:173-189.
27. Broccia G, Deplano W, Dessalvi P, et al. Hematological malignancies in the island of Sardinia, 1974-1993: Age and sex distributions and temporal changes in incidence. Hematol Oncol 2004;22:91-109.
28. Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: A population-based study. Haematologica 2009;94:865-869.
29. Troussard X, Duchenet V, Cornet E, et al. Haematological malignancies: Incidence in Basse-Normandie, France, for 1997-2004. Rev Epidemiol Sante Publique 2009;57:151-158.
30. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
31. Castellano PG, Garcia EF, Perez MB, et al. Ageing of the population and number of acquired primary blood diseases in one area of the autonomous region of Aragon. Rev Esp Salud Publ 1998;72:559-570.
32. Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: An epidemiological study of 29 cases. Med J Aust 1976;1:523-525.
33. Veselovska J, Pospisilova D, Pekova S, et al. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies. Leuk Res 2008;32:369-377.
34. Reis R de S, de Camargo B, Santos M de O, et al. Childhood leukemia incidence in Brazil according to different geographical regions. Pediatr Blood Cancer 2011;56:58-64.
35. Chaiter Y, Brenner B, Aghai E, et al. High-incidence of myeloproliferative disorders in Ashkenazi jews in Northern Israel. Leuk Lymph 1992;7:251-255.
36. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood 2010;116:3724-3734.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
38. Thomas T, Abrams KR, De Caestecker JS, et al. Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007;26:1465-1477.
39. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: Cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007;25:657-668.
40. StataCorp. Stata Statistical Software: Release 12. College Station, TX; 2011.
41. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-1692.
42. Watters A. Haematological malignancies Thames Valley cancer network. 2010;49:45.
43. Craft A, Amineddine H, Scott J, et al. The Northern region Children's malignant disease registry 1968-1982: Incidence and survival. Br J Cancer 1987;56:853-858.
44. Waterhouse JAH. Cancer Handbook of Epidemiology. Edinburgh and London: Churchill Livingstone 1974. pp 191-192.
45. MPN Research Foundation. MPN prevalence by the numbers; 2013. p 1.
46. Thompson R, Cuthbert RJ, Boyd HK, et al. Essential Thrombocythaemia in Northern Ireland: Prevalence and Pattern of Disease. 2008; p 1.
47. Kurita S. Epidemiological studies of polycythemia vera in Japan (author's transl). Nihon Ketsueki Gakkai Zasshi 1974;37:793-795.
48. Johansson P, Kutti J, Andréasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-1999. J Intern Med 2004;256:161-165.
49. Lickiss JN, Giles GG, Baikie MJ. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-1980: Patterns in space and time. J Natl Cancer 1984;72:1223-1231.
50. Silverstein MN, Lanier AP. Polycythemia vera, 1935-1969: An epidemiologic survey in Rochester, Minnesota. Mayo Clin Proc Mayo Clin 1971;46:751-753.
51. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992;48:20-26.
52. Modan B. An epidemiological study of polycythemia vera. Blood 1965;26:657-667.
53. Modan B, Kallner H, Zemer D, et al. A note on the increased risk of polycythemia vera in Jews. Blood 1971;37:172-176.
54. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009;23:602-604.
55. Phekoo KJ, Richards MA, Moller H, et al. The incidence and outcome of myeloid malignancies in 2, 112 adult patients in south East-England. Haematologica 2006;91:1400-1404.
56. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An olmsted county study, 1976-1995. Am J Hematol 1999;61:10-15.
57. Reid MM, Saunders PW, Kernahan J. Myeloproliferative disease in children: A demographic study. J Clin Pathol 1988;41:883-885.
58. Jensen MK, De Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-139.
59. Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008;83:359-362.
60. Visser O, Trama A, Maynadie M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012;48:3257-3266.
61. Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelfibrosis (Mf), essential thrombocythemia (Et), and polycythemia vera (Pv) in the European union (Eu). Eur J Haematol 2013. [Epub ahead of print].
62. Ania BJ, Suman VJ, Sobell JL, et al. Trends in the incidence of polycythemia vera among Olmsted county, Minnesota residents, 1935-1989. Am J Hematol 1994;47:89-93.
63. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
64. Bentley MA, Taylor KM, Wright SJ. Essential thrombocythaemia. Med J Aust 1999;171:210-213.
65. Osborne W, Jones GL, Jackson GH, et al. Myeloproliferative disorders in older people. Rev Clin Gerontol 2012;22:108-118.
66. Malmqvist G, Nerander KG, Larson M. Sjunet-The national IT infrastructure for healthcare in Sweden. Stud Health Technol Inform 2004;100:41-49.
67. Tingle J. The state of health care and adult social care in England. Br J Nurs 2011;20:760-761.
68. López-Gómez M, Malmierca E, de Górgolas M, et al. Cancer in developing countries: The next most preventable pandemic. The global problem of cancer. Crit Rev Oncol Hematol 2013;20:760-761.
69. Arkin DMP, Ray FB, Erlay JF, et al. Mini review estimating the world cancer burden : GLOBOCAN 2000 2001;156:153-156.
70. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 61:69-90.
71. Bray F, Ren J-S, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-1145.
72. Office for National Statistics [Internet]. 2013. Available from: http://www.ons.gov.uk/ons/index.html. Accessed date 22 november 2013.
73. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76.
74. Hoffbrand AV, Moss PAH, Pettit JE. Essential Haematology, 5th ed. Oxford: Blackwell Publishing; 2006.
75. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
76. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012;30:2981-2987.
77. Price GL, Pohl GM, Xie J, et al. A retrospective observational study of annual healthcare costs for patients with forms of myeloproliferative neoplasms (MPN). ASCO Abstr 2011.
78. Valsecchi MG, Steliarova-Foucher E. Cancer registration in developing countries: luxury or necessity? Lancet Oncol 2008;9:159-167.